| Assessment Status | Rapid Review Complete |
| HTA ID | 26010 |
| Drug | Tislelizumab |
| Brand | Tevimbra® |
| Indication | Tislelizumab (Tevimbra®) in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of adult patients with squamous non-small cell lung cancer (NSCLC) who have: • locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or • metastatic NSCLC. |
| Assessment Process | |
| Rapid review commissioned | 11/03/2026 |
| Rapid review completed | 10/04/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tislelizumab (Tevimbra®)not be considered for reimbursement at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be foundhere
Further information on the status of this decision may be found here